Physician profile
Jon E Binkerd
NPI 1962685545
$413.00
in general payments reported to CMS, 2019-2025
15 companies · $21.96 in 2025
The $21.96 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.85 · 2020: $14.42 · 2021: $56.17 · 2022: $133 · 2023: $59.12 · 2024: $102 · 2025: $21.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $183.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $73.60 | 2022 | |
| Solventum Corporation | $52.69 | 2024-2025 | Activ.A.C. Ion Progress, Activ.A.C. |
| Tela Bio, INC. | $45.66 | 2023-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Braintree Laboratories, INC. | $40.74 | 2021-2024 | Suflave, Sutab |
| Boston Scientific Corporation | $28.86 | 2021 | |
| Abbvie INC. | $27.30 | 2022 | |
| Thd America, INC. | $23.07 | 2024 | |
| Kci USA, INC. | $17.85 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.67 | 2023 | Nuzyra |
| Innocoll Pharmaceuticals Limited | $16.12 | 2021 | |
| Medtronic, INC. | $15.17 | 2024 | Gia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.00 | 2023 | Xifaxan |
| Redhill Biopharma INC. | $14.42 | 2020 | |
| Allergan, INC. | $12.93 | 2019 | |
| Misonix INC | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Binkerd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.